Forsgård R, 2023
Sweden
To investigate if supplementation of L. reuteri DSM 17938 increases the anti-SARS-CoV-2 antibody response upon infection or vaccination.
R, DB, PC 6 months
L. reuteri: 81 (2×108 CFU) Placebo: 78
L. reuteri supplementation resulted in significantly increased SARS-CoV-2-specific IgG and IgA levels after >28 days post SARS-CoV-2 vaccination. Also, a tendency towards increased CoV-2-specific IgG levels after SARS-CoV-2 infection was observed.
Tubelius P, 2005
Sweden
To study prevention of short-term illness, cold or GI infection, in heal thy adults at a work place.
R, DB, PC 80 days
L. reuteri: 94 (1×108 CFU) Placebo: 87
L. reuteri significantly reduced short-term sick leave due to cold or GI infection compared to placebo: 10.6% and 26.4%, respectively, reported sick-leave. Among the in total 53 shift workers, the frequency was 0 vs. 33%.
Di Nardo G, 2014
Italy
The aim of this study was to evalua te the effect of L. reuteri DSM 17938 in patients with cystic fibrosis, with mild-to-moderate lung disease aged 6-29y (median age 18y), on the rate of respiratory exacerbations and of infections of the upper respi ratory and the GI tracts.
NOTE: The right designation of the probiotic strain of this trial is L. reuteri DSM 17938, not ATCC 55730 as sta ted in the paper.
R, DB, PC 6 months
L. reuteri: 30 (1×108 CFU) Placebo: 30
Compared to placebo, L. reuteri significantly:
• Reduced the frequency of pulmonary exacerbations
• Reduced the number of upper respiratory tract infections = only otitis
The groups did not differ statistically in the mean number and duration of hospitalizations for pulmonary exacerbations and gastrointestinal infections.
There was no effect on lung function (mean delta value of FEV1), faecal calprotectin concentration, and tested cytokines (tumour necrosis factor-a and interleukin-8) between the two groups.
Schröder C, 2015
Germany
The effect of regular intake of L. reuteri DSM 17938 on the number of days of sick leave caused by respiratory and/or gastrointestinal diseases among male steelworkers.
R, DB, PC 90 days
L. reuteri: 79 (1×108 CFU) Placebo: 80 Randomized: 242
L. reuteri significantly reduced the incidence of diarrhoea, which was reported on 0.60 days for subjects of the L. reuteri group vs. 1.33 days in the placebo group.
There was no difference in primary outcome of number of sick days due to respiratory or gastrointestinal symptoms. The drop-out rate of randomized subjects was 34%.